Sirius XM Holdings Attracts Investors With New SiriusXM Onyx Plus (NASDAQ:SIRI)

Sirius XM Holdings Inc. (NASDAQ:SIRI)

As technology stocks lifted the NASDAQ Composite to a 13 year high, check out Sirius XM Holdings ticker symbol SIRI. The Stock experienced a +2.31 percentage gain Up 0.09 generating above 29.8 million shares in the financial markets Friday November 29, 2013. Sirius XM Holdings is the world’s largest radio broadcaster with over 25.6 million subscribers providing more than substantial income concerning the Company’s revenue. Why is the Stock generating over 29.8 million shares in the wall street financial district you ask? The answer is absolutely the new SiriusXM Onyx Plus.

SiriusXM Onyx Plus isn’t only intriguing investors globally, it has simply captivated stock market research analyst as it availability spreads throughout U.S. Best Buy stores and via the web (http://shop.siriusxm.com/xm/ctl10600/cp49759/si6424140/cl1/) with a asking price of under $100. SiriusXM Onyx Plus  offers a full-color album art display, smart favorite channel programming, TuneMix™, TuneStart™ and TuneScan™ while providing a commercial free experience while listening to its music channels. As Sirius XM Holdings continues to enlarge its channel lineup, don’t deny the fact that this Company (www.siriusradio.com) holds a minority interest in SiriusXM Canada. SiriusXM Canada is a Company that reported record yearly revenue of $288.9 million , surging +11.3% year over year.  

****

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

While stock market analyst speculate the holiday seasons jobs data and retail figures, take a look at Ariad Pharmaceuticals Inc. ticker symbol ARIA.  The Stock experienced a +6.61 percentage gain Up 0.30 generating above 20.4 million shares in the financial markets Friday November 29, 2013. Ariad Pharmaceuticals is an integrated global oncology company specializing in areas of cancer with innovative breakthrough medicines. Why is the Stock generating over 20.4 million shares in the wall street financial district you ask? The answer is Iclusig.

Iclusig is used to treat a type of blood cancer called chronic myeloid leukemia, or Philadelphia chromosome positive acute lymphoblastic leukemia. The medicine interferes with process of some cancer cells increasing in physical size. Cancer therapies in the global market are expected to reach over $110.6 billion by the end of year 2013. The Company (www.ariad.com) previously announced a positive opinion by the European Medicines Agency on the ongoing accessibility of Iclusig in Patients with Leukaemias.

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/